机译:一线升级的 BEACOPP 不会阻碍复发/难治性霍奇金淋巴瘤患者的干细胞收集和移植策略
Gustave Roussy, Dept Hematol, Villejuif, France;
EORTC Headquarters, Brussels, Belgium;
CHU Archet, Dept Oncohematol, Nice, FranceCHU Nancy Brabois, Dept Hematol, Vandoeuvre Les Nancy, FranceNatl Canc Inst, Dept Med Oncol, Cairo, EgyptUniv Paris Diderot, Hop St Louis, APHP, Dept Oncol & Hematol, Paris, FranceHop Henri Mondor, Unite Hemopathies Lymphoides, Creteil, FranceUmea Univ, Dept Oncol, Umea, SwedenUniv Lille 2, Dept Clin Hematol, Hop Claude Huriez, Lille, FranceCtr Henri Becquerel, Dept Hematol, Rouen, FranceUniv Picardie Jules Verne, CHU Amiens, Dept Hematol, Amiens, FranceLeon Berard Canc Ctr, Dept Hematol, Lyon, FranceCHU Dijon, Dept Hematol, Dijon, France;
机译:Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance
机译:Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma
机译:Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
机译:Validação do Escore de Risco do EBmT em 1.084 pacientes portadores de leucemia mielóide crônica submetidos ao transplante alogênico de células precursoras hematopoiéticas no Brasil allogeneic hematopoietic stem cell transplantation - EBmT risk score validation in 1084 chronic myeloid leukemia patients transplanted in Brazil